The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
The Body Covers:
The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy
Toronto, Canada

September 13-15, 2000

Pablo Tebas, M.D.
Pablo Tebas, M.D.
Recent years have seen countless reports of metabolic abnormalities in HIV-infected people treated with highly active antiretroviral therapy (HAART). Manifestations of these metabolic abnormalities include facial wasting, breast enlargement, and "buffalo hump," among other complications. Little is understood about this syndrome, called lipodystrophy, and that's why a conference was initiated in 1999 -- the First International Workshop on Adverse Drug Reactions and Lipodystrophy -- to address these problems. This year's conference will be held in Toronto and The Body is pleased to have Dr. Pablo Tebas covering it. Dr. Tebas is an Assistant Professor of Medicine at Washington University School of Medicine, medical director of the oupatient clinic of the Infectious Diseases Division, and investigator in the AIDS Clinical Trial Unit at Washington University.

Funding for this conference coverage at the Body is provided, in part, through unrestricted educational grants by Bio-Technology Group Corp. and Glaxo Wellcome.

The Body's Conference Summaries
Day Two
September 14
Day Three
September 15


Physiology of Lipoatrophy

Lessons from Lipodystrophic Mice: A Vicious Cycle

Inborn and Induced Defects of the Mitochondrial Respiratory Chain

Decrease of Mitochondrial DNA Content in Adipose Tissue of HIV-1 Infected Patients Treated with NRTIs

Subcutaneous Adipose-Tissue Mitochondrial DNA Analysis from Individuals with HAART-Associated Lipodystrophy

Metabolic Effects of Indinavir in Healthy HIV Seronegative Subjects

Assessment of Growth Hormone Physiology in the HIV Lipodystrophy Syndrome

The Effects of Recombinant Human Growth Hormone (GH) on Glucose Metabolism and Body Composition in HIV-Positive Subjects with Fat Accumulation (FA) Syndromes

Genes, Diet, and Atherogenic Dyslipidemia

HIV Protease Inhibitors Increase Secretion of Apolipoprotein B-lipoproteins from Hepatoma Cells by Preventing Proteasomal Degradation

Differences in Postprandial Lipid Metabolism in Patients with PI-Associated and NRTI-Associated Lipodystrophy

Increased tPA Antigen Levels in the HIV Lipodystrophy Syndrome are Reduced in Response to Metformin

Role of Endothelial Dysfunction in Atherosclerosis

Metabolic Complications: The Need for Perspective

Use of HIV Protease Inhibitors is Associated with Endothelial Dysfunction

IMT as Cardiovascular Risk Marker in HIV+ Patients Treated and Untreated with Protease Inhibitors

Lessons Learned from Switching Antivirals

Lipodystrophy and Metabolic Abnormalities in a Cross-Sectional Study of Participants in Randomized-Controlled Studies of Combination Antiretroviral Therapy (ARV)

Serum and Urine Markers of Bone Mineral Metabolism in HIV-Infected Patients Taking Protease Inhibitor-Containing Potent Antiretroviral Therapy

Longitudinal Analysis of Bone Mineral Density (BMD) in HIV-infected Patients Treated with HAART: Changes in BMD Correlate with Change in Subcutaneous Fat; with an Additional Independent Effect of Indinavir Therapy to Increase BMD

Osteopenia in HIV-Infected Men: Association with Lactic Acidemia and Lower Weight Pre-Antiretroviral Therapy

Case-control Study of Avascular Necrosis (AVN) in HIV-Infected Patients

Metabolic and Clinical Evaluation of Lipodystrophy 48 Weeks After Switching from Two Nucleoside Reverse Transcriptase Inhibitors/Protease Inhibitor to Two Nucleoside Reverse Transcriptase Inhibitors/Abacavir (French Substudy, CNA 30017)

Switching from Protease Inhibitor to Nevirapine-Based Potent Antiretroviral Therapy Increases Lean Body Mass

HIV-Protease Inhibitor Switch to Nevirapine Improves Insulin Tolerance but Does not Correct Adipose Tissue Maldistribution

A Randomized, Multicentre Study of Protease Inhibitor Substitution in Aviraemic Patients with Lipodystrophy (LD): 48-Week Data

Fat Redistribution Syndrome/Lipodystrophy and Anabolic Agents: Results of a Large Multicenter U.S. Study

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.